Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bodyl A Brand

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
The Lancet. Psychiatry|March 27, 2026
Women and psychosis: a guide to evidence-based, hormone-informed careBodyl A Brand, Sophie Behrman, Katie F M Marwick, et al.
Schizophrenia Bulletin|April 28, 2023
The Direct and Long-Term Effects of Raloxifene as Adjunctive Treatment for Schizophrenia-Spectrum Disorders: A Double-Blind, Randomized Clinical TrialBodyl A Brand, Janna N de Boer, Machteld C Marcelis, et al.
Schizophrenia Bulletin|March 21, 2026
The Impact of Sex and Age on Antipsychotic Serum ConcentrationsFranciska de Beer, Bodyl A Brand, Ben Wijnen, et al.
Psychological Medicine|November 12, 2021
Antipsychotic medication for women with schizophrenia spectrum disordersBodyl A Brand, Yudith R A Haveman, Franciska de Beer, et al.
Archives of Women'S Mental Health|July 12, 2024
Antipsychotic-induced prolactin elevation in premenopausal women with schizophrenia: associations with estrogen, disease severity and cognitionBodyl A Brand, Janna N de Boer, Elske J M Willemse, et al.
Schizophrenia Bulletin|March 21, 2026
Practical Approach to Hormone Replacement Therapy for (Peri) Menopausal Women With Schizophrenia Spectrum Disorders: A Case SeriesKirsten E Noot, Bodyl A Brand, Iris M H Hamers, et al.
Psychoneuroendocrinology|January 12, 2025
Genetic variants in COMT and ESR1 genes shape treatment response to raloxifene in schizophrenia-spectrum disordersBodyl A Brand, Anne Jetske Boer, Janna N de Boer, et al.
Psychological Medicine|May 10, 2023
Antipsychotic medication for women with schizophrenia spectrum disorders - CORRIGENDUMBodyl A Brand, Yudith R A Haveman, Franciska de Beer, et al.
Schizophrenia Research|June 30, 2024
The association of prolactin and gonadal hormones with cognition and symptoms in men with schizophrenia spectrum disorder: Divergent effects of testosterone and estrogenIris M H Hamers, Bodyl A Brand, Marieke J H Begemann, et al.
Journal of Psychopathology and Clinical Science|March 1, 2022
Characterizing speech heterogeneity in schizophrenia-spectrum disordersPriscilla P Oomen, Janna N de Boer, Sanne G Brederoo, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
The Lancet. Psychiatry|March 27, 2026
Women and psychosis: a guide to evidence-based, hormone-informed careBodyl A Brand, Sophie Behrman, Katie F M Marwick, et al.
Schizophrenia Bulletin|April 28, 2023
The Direct and Long-Term Effects of Raloxifene as Adjunctive Treatment for Schizophrenia-Spectrum Disorders: A Double-Blind, Randomized Clinical TrialBodyl A Brand, Janna N de Boer, Machteld C Marcelis, et al.
Schizophrenia Bulletin|March 21, 2026
The Impact of Sex and Age on Antipsychotic Serum ConcentrationsFranciska de Beer, Bodyl A Brand, Ben Wijnen, et al.
Psychological Medicine|November 12, 2021
Antipsychotic medication for women with schizophrenia spectrum disordersBodyl A Brand, Yudith R A Haveman, Franciska de Beer, et al.
Archives of Women'S Mental Health|July 12, 2024
Antipsychotic-induced prolactin elevation in premenopausal women with schizophrenia: associations with estrogen, disease severity and cognitionBodyl A Brand, Janna N de Boer, Elske J M Willemse, et al.
Schizophrenia Bulletin|March 21, 2026
Practical Approach to Hormone Replacement Therapy for (Peri) Menopausal Women With Schizophrenia Spectrum Disorders: A Case SeriesKirsten E Noot, Bodyl A Brand, Iris M H Hamers, et al.
Psychoneuroendocrinology|January 12, 2025
Genetic variants in COMT and ESR1 genes shape treatment response to raloxifene in schizophrenia-spectrum disordersBodyl A Brand, Anne Jetske Boer, Janna N de Boer, et al.
Psychological Medicine|May 10, 2023
Antipsychotic medication for women with schizophrenia spectrum disorders - CORRIGENDUMBodyl A Brand, Yudith R A Haveman, Franciska de Beer, et al.
Schizophrenia Research|June 30, 2024
The association of prolactin and gonadal hormones with cognition and symptoms in men with schizophrenia spectrum disorder: Divergent effects of testosterone and estrogenIris M H Hamers, Bodyl A Brand, Marieke J H Begemann, et al.
Journal of Psychopathology and Clinical Science|March 1, 2022
Characterizing speech heterogeneity in schizophrenia-spectrum disordersPriscilla P Oomen, Janna N de Boer, Sanne G Brederoo, et al.
Pageof 3